|
May 8
|
Bionano Genomics (BNGO) Q1 2024 Earnings Call Transcript
|
|
May 8
|
Bionano Reports First Quarter 2024 Results and Highlights Recent Business Progress
|
|
May 1
|
Bionano to Report First Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 8, 2024
|
|
Apr 30
|
Bionano to Present at the RBC Capital Markets 2024 Global Healthcare Conference
|
|
Apr 25
|
3 Contrarian Investments to Make Now for Massive Upside Potential
|
|
Apr 24
|
Bionano Announces Publication Showing OGM’s High Resolution Structural Variation Detection in Cancer Validated by Cas9-Directed Nanopore Sequencing
|
|
Apr 17
|
Bionano and Diagens Sign Partnership to Commercialize the First Ever Clinical Cytogenetic Analysis that Combines OGM and Artificial Intelligence
|
|
Apr 11
|
Bionano Announces Publication Showing that OGM Detects Over 1250 Structural Variants, including 56 Gene Fusions, in Pediatric Leukemia that were Missed by Whole Genome Sequencing
|
|
Apr 4
|
Bionano Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
|
|
Apr 3
|
Bionano Announces Publication Showing that OGM Identifies Genetic Aberrations in Sarcoma Samples that May Lead to Improved Diagnosis but were Missed by Classical Cytogenetics
|
|
Apr 2
|
Bionano Announces 9 Poster Presentations and Introduces New High Throughput Stratys™ System at the American Association for Cancer Research Annual Meeting
|
|
Mar 19
|
Bionano Announces Publication of a Breast Cancer Study Showing that the Number of SVs Detected with OGM May Be Related to Prognosis, Tumor Progression and Chemotherapy Resistance
|
|
Mar 7
|
Bionano Genomics, Inc. (NASDAQ:BNGO) Q4 2023 Earnings Call Transcript
|
|
Mar 7
|
Bionano Announces Extensive Lineup of Content at American College of Medical Genetics and Genomics (ACMG) Annual Meeting Including Live Product Showcase Featuring the Company’s New Stratys™ System
|
|
Mar 6
|
Q4 2023 Bionano Genomics Inc Earnings Call
|
|
Mar 6
|
Bionano Genomics (BNGO) Q4 2023 Earnings Call Transcript
|
|
Mar 5
|
Bionano Reports Fourth Quarter and Full-Year 2023 Results and Provides Revenue Outlook for 2024
|
|
Jan 11
|
Bionano Announces Peer-Reviewed Publication from its Clinical Study Designed to Support OGM as Part of Standard of Care (SOC) in Genetic Disease Testing
|
|
Jan 10
|
Bionano Announces 2024 Symposium: Four Consecutive Days of OGM Presentations and Live Panel Discussions Across a Wide Range of Research Applications
|
|
Dec 28
|
Bionano Announces Significant Upgrades to its Bionano Solve Pipeline and its VIA™ Software for OGM Data Analysis in Constitutional Genetic Disease Research
|